Skip to main content

Intradialytic Hypotension

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Ear pillsPhase 2/31 trial
Active Trials
NCT02583802Unknown150Est. Dec 2015
Pharvaris
PharvarisNetherlands - Leiden
1 program
IcatibantPHASE_31 trial
Active Trials
NCT05834777Active Not Recruiting26Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharvarisIcatibant
Integrated BiosciencesEar pills

Clinical Trials (2)

Total enrollment: 176 patients across 2 trials

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Start: Dec 2023Est. completion: Nov 202626 patients
Phase 3Active Not Recruiting

The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients

Start: Sep 2013Est. completion: Dec 2015150 patients
Phase 2/3Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.